P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality?
BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded...
Gespeichert in:
Veröffentlicht in: | Thorax 2017-12, Vol.72 (Suppl 3), p.A175 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Suppl 3 |
container_start_page | A175 |
container_title | Thorax |
container_volume | 72 |
creator | Sharp, C Grove, A Augustine, D Carson, K Easaw, J Hall, T Hudson, B Robinson, G Coghlan, G Mackenzie-Ross, R Suntharalingam, J |
description | BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded Red (high), Amber (medium) and Green (low). It is unclear whether these criteria are associated with short term survival.AimTo determine whether red/amber/green risk status according to ESC guidelines is associated with 12 month mortality.MethodsThis was a “snapshot” observational study using routinely collected clinical data for patients eligible for targeted drug treatment at a regional centre, under shared care with a national centre. All data available at the latest visit within the study period were collated, including demographics, echocardiogram and right heart catheterisation data. Data are reported as mean/median/count/%. Characteristics of deceased and surviving patients were compared using Mann-Witney U-test. Association with 12 month mortality was assessed using Receiver Operator Characteristics (ROC) curve analysis.ResultsRoutinely collected clinic data were available for 104 patients, echocardiograms for 88 and right heart catheter data for 68. 25% were male, mean age 68.2 years. 45.2% had connective tissue disease-associated PAH, 32.7% inoperable chronic thromboembolic PH, 18.3% Idiopathic PAH. 101 were on treatment, of which 35.6% were on monotherapy, 51.0% on dual oral therapy, 9.6% on intravenous treatments. Baseline data are shown in the table. 25% had one red criterion, 14.4% had two and 8.6% had three or more. 19 patients died in the 12 month follow-up period, 6 of whom had no red criteria. Deceased patients were older (p=0.015) and had shorter walking distance (p=0.003). Risk criteria were worse for symptom progression, WHO functional class, walking distance and for the overall number of red criteria. ROC-curve analysis showed that symptom progression (c-statistic 0.695, p=0.048), walking distance (0.748, p=0.012) and the overall number of red flags (0.710, p=0.033) were the only elements associated with 12 month mortality.Abstract P171 Table 1Median/%Red flags, n(%) Symptom progressionN/A11 (10.6)NT-proBNP (ng/L)60.52 (1.9)WHO functional classN/A13 (12.5)6 min walk distance (m)29528 (28)Echo RA area (cm2)17.5 5 (7.4)Right heart catheter (any criterion)N/A13 (19.1)ConclusionsThe ESC risk assessment criteria are associated with 12 month mor |
doi_str_mv | 10.1136/thoraxjnl-2017-210983.313 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_1970930940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1970930940</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1243-5a86e675db833317472e9b0d6e1138d9cbb38d021fc0bd2ed7132cbf8f4bc3543</originalsourceid><addsrcrecordid>eNo9kMFq3DAQhkVoINtN30ElZ6cayWvZp7AsaVpYaA_tWUj2eK2tbTmSTOJbLjn1LfMk0bKlp38Yfr5hPkI-A7sFEMWX2Dmvn49jn3EGMuPAqlLcChAXZAV5UWaCV8UHsmIsZ1khZHFFPoZwZIyVAHJF_v4ECW8vr1uPNHZIcfZuQj3S4GqLcaGupbX2jXW9Oyx0mvvBjdovtFsm9BHHYN1ID7NtsLcjUm_DH6pDwBAGHCOtvY3orT7tElFHbOiTjR0FniVSGgbno-5tXO6uyWWr-4Cf_uWa_P56_2v3Ldv_ePi-2-4zAzwX2UaXBRZy05hSCAEylxwrw5oCk5GyqWpjUjAObc1Mw7GRIHht2rLNTS02uViTmzN38u5xxhDV0c1-TCcVVJJVglU5S6383DLDUU3eDulrBUydtKv_2tVJuzprV0m7eAdZ2nym</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1970930940</pqid></control><display><type>article</type><title>P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality?</title><source>Alma/SFX Local Collection</source><creator>Sharp, C ; Grove, A ; Augustine, D ; Carson, K ; Easaw, J ; Hall, T ; Hudson, B ; Robinson, G ; Coghlan, G ; Mackenzie-Ross, R ; Suntharalingam, J</creator><creatorcontrib>Sharp, C ; Grove, A ; Augustine, D ; Carson, K ; Easaw, J ; Hall, T ; Hudson, B ; Robinson, G ; Coghlan, G ; Mackenzie-Ross, R ; Suntharalingam, J</creatorcontrib><description>BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded Red (high), Amber (medium) and Green (low). It is unclear whether these criteria are associated with short term survival.AimTo determine whether red/amber/green risk status according to ESC guidelines is associated with 12 month mortality.MethodsThis was a “snapshot” observational study using routinely collected clinical data for patients eligible for targeted drug treatment at a regional centre, under shared care with a national centre. All data available at the latest visit within the study period were collated, including demographics, echocardiogram and right heart catheterisation data. Data are reported as mean/median/count/%. Characteristics of deceased and surviving patients were compared using Mann-Witney U-test. Association with 12 month mortality was assessed using Receiver Operator Characteristics (ROC) curve analysis.ResultsRoutinely collected clinic data were available for 104 patients, echocardiograms for 88 and right heart catheter data for 68. 25% were male, mean age 68.2 years. 45.2% had connective tissue disease-associated PAH, 32.7% inoperable chronic thromboembolic PH, 18.3% Idiopathic PAH. 101 were on treatment, of which 35.6% were on monotherapy, 51.0% on dual oral therapy, 9.6% on intravenous treatments. Baseline data are shown in the table. 25% had one red criterion, 14.4% had two and 8.6% had three or more. 19 patients died in the 12 month follow-up period, 6 of whom had no red criteria. Deceased patients were older (p=0.015) and had shorter walking distance (p=0.003). Risk criteria were worse for symptom progression, WHO functional class, walking distance and for the overall number of red criteria. ROC-curve analysis showed that symptom progression (c-statistic 0.695, p=0.048), walking distance (0.748, p=0.012) and the overall number of red flags (0.710, p=0.033) were the only elements associated with 12 month mortality.Abstract P171 Table 1Median/%Red flags, n(%) Symptom progressionN/A11 (10.6)NT-proBNP (ng/L)60.52 (1.9)WHO functional classN/A13 (12.5)6 min walk distance (m)29528 (28)Echo RA area (cm2)17.5 5 (7.4)Right heart catheter (any criterion)N/A13 (19.1)ConclusionsThe ESC risk assessment criteria are associated with 12 month mortality in this cohort when all criteria are collated. Further work in a large cohort is needed to confirm the clinical utility of these criteria.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thoraxjnl-2017-210983.313</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Cardiology ; Medical prognosis ; Mortality ; Pulmonary hypertension ; Risk assessment ; Walking</subject><ispartof>Thorax, 2017-12, Vol.72 (Suppl 3), p.A175</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids></links><search><creatorcontrib>Sharp, C</creatorcontrib><creatorcontrib>Grove, A</creatorcontrib><creatorcontrib>Augustine, D</creatorcontrib><creatorcontrib>Carson, K</creatorcontrib><creatorcontrib>Easaw, J</creatorcontrib><creatorcontrib>Hall, T</creatorcontrib><creatorcontrib>Hudson, B</creatorcontrib><creatorcontrib>Robinson, G</creatorcontrib><creatorcontrib>Coghlan, G</creatorcontrib><creatorcontrib>Mackenzie-Ross, R</creatorcontrib><creatorcontrib>Suntharalingam, J</creatorcontrib><title>P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality?</title><title>Thorax</title><description>BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded Red (high), Amber (medium) and Green (low). It is unclear whether these criteria are associated with short term survival.AimTo determine whether red/amber/green risk status according to ESC guidelines is associated with 12 month mortality.MethodsThis was a “snapshot” observational study using routinely collected clinical data for patients eligible for targeted drug treatment at a regional centre, under shared care with a national centre. All data available at the latest visit within the study period were collated, including demographics, echocardiogram and right heart catheterisation data. Data are reported as mean/median/count/%. Characteristics of deceased and surviving patients were compared using Mann-Witney U-test. Association with 12 month mortality was assessed using Receiver Operator Characteristics (ROC) curve analysis.ResultsRoutinely collected clinic data were available for 104 patients, echocardiograms for 88 and right heart catheter data for 68. 25% were male, mean age 68.2 years. 45.2% had connective tissue disease-associated PAH, 32.7% inoperable chronic thromboembolic PH, 18.3% Idiopathic PAH. 101 were on treatment, of which 35.6% were on monotherapy, 51.0% on dual oral therapy, 9.6% on intravenous treatments. Baseline data are shown in the table. 25% had one red criterion, 14.4% had two and 8.6% had three or more. 19 patients died in the 12 month follow-up period, 6 of whom had no red criteria. Deceased patients were older (p=0.015) and had shorter walking distance (p=0.003). Risk criteria were worse for symptom progression, WHO functional class, walking distance and for the overall number of red criteria. ROC-curve analysis showed that symptom progression (c-statistic 0.695, p=0.048), walking distance (0.748, p=0.012) and the overall number of red flags (0.710, p=0.033) were the only elements associated with 12 month mortality.Abstract P171 Table 1Median/%Red flags, n(%) Symptom progressionN/A11 (10.6)NT-proBNP (ng/L)60.52 (1.9)WHO functional classN/A13 (12.5)6 min walk distance (m)29528 (28)Echo RA area (cm2)17.5 5 (7.4)Right heart catheter (any criterion)N/A13 (19.1)ConclusionsThe ESC risk assessment criteria are associated with 12 month mortality in this cohort when all criteria are collated. Further work in a large cohort is needed to confirm the clinical utility of these criteria.</description><subject>Cardiology</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Pulmonary hypertension</subject><subject>Risk assessment</subject><subject>Walking</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kMFq3DAQhkVoINtN30ElZ6cayWvZp7AsaVpYaA_tWUj2eK2tbTmSTOJbLjn1LfMk0bKlp38Yfr5hPkI-A7sFEMWX2Dmvn49jn3EGMuPAqlLcChAXZAV5UWaCV8UHsmIsZ1khZHFFPoZwZIyVAHJF_v4ECW8vr1uPNHZIcfZuQj3S4GqLcaGupbX2jXW9Oyx0mvvBjdovtFsm9BHHYN1ID7NtsLcjUm_DH6pDwBAGHCOtvY3orT7tElFHbOiTjR0FniVSGgbno-5tXO6uyWWr-4Cf_uWa_P56_2v3Ldv_ePi-2-4zAzwX2UaXBRZy05hSCAEylxwrw5oCk5GyqWpjUjAObc1Mw7GRIHht2rLNTS02uViTmzN38u5xxhDV0c1-TCcVVJJVglU5S6383DLDUU3eDulrBUydtKv_2tVJuzprV0m7eAdZ2nym</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Sharp, C</creator><creator>Grove, A</creator><creator>Augustine, D</creator><creator>Carson, K</creator><creator>Easaw, J</creator><creator>Hall, T</creator><creator>Hudson, B</creator><creator>Robinson, G</creator><creator>Coghlan, G</creator><creator>Mackenzie-Ross, R</creator><creator>Suntharalingam, J</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201712</creationdate><title>P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality?</title><author>Sharp, C ; Grove, A ; Augustine, D ; Carson, K ; Easaw, J ; Hall, T ; Hudson, B ; Robinson, G ; Coghlan, G ; Mackenzie-Ross, R ; Suntharalingam, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1243-5a86e675db833317472e9b0d6e1138d9cbb38d021fc0bd2ed7132cbf8f4bc3543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cardiology</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Pulmonary hypertension</topic><topic>Risk assessment</topic><topic>Walking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharp, C</creatorcontrib><creatorcontrib>Grove, A</creatorcontrib><creatorcontrib>Augustine, D</creatorcontrib><creatorcontrib>Carson, K</creatorcontrib><creatorcontrib>Easaw, J</creatorcontrib><creatorcontrib>Hall, T</creatorcontrib><creatorcontrib>Hudson, B</creatorcontrib><creatorcontrib>Robinson, G</creatorcontrib><creatorcontrib>Coghlan, G</creatorcontrib><creatorcontrib>Mackenzie-Ross, R</creatorcontrib><creatorcontrib>Suntharalingam, J</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharp, C</au><au>Grove, A</au><au>Augustine, D</au><au>Carson, K</au><au>Easaw, J</au><au>Hall, T</au><au>Hudson, B</au><au>Robinson, G</au><au>Coghlan, G</au><au>Mackenzie-Ross, R</au><au>Suntharalingam, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality?</atitle><jtitle>Thorax</jtitle><date>2017-12</date><risdate>2017</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A175</spage><pages>A175-</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><abstract>BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded Red (high), Amber (medium) and Green (low). It is unclear whether these criteria are associated with short term survival.AimTo determine whether red/amber/green risk status according to ESC guidelines is associated with 12 month mortality.MethodsThis was a “snapshot” observational study using routinely collected clinical data for patients eligible for targeted drug treatment at a regional centre, under shared care with a national centre. All data available at the latest visit within the study period were collated, including demographics, echocardiogram and right heart catheterisation data. Data are reported as mean/median/count/%. Characteristics of deceased and surviving patients were compared using Mann-Witney U-test. Association with 12 month mortality was assessed using Receiver Operator Characteristics (ROC) curve analysis.ResultsRoutinely collected clinic data were available for 104 patients, echocardiograms for 88 and right heart catheter data for 68. 25% were male, mean age 68.2 years. 45.2% had connective tissue disease-associated PAH, 32.7% inoperable chronic thromboembolic PH, 18.3% Idiopathic PAH. 101 were on treatment, of which 35.6% were on monotherapy, 51.0% on dual oral therapy, 9.6% on intravenous treatments. Baseline data are shown in the table. 25% had one red criterion, 14.4% had two and 8.6% had three or more. 19 patients died in the 12 month follow-up period, 6 of whom had no red criteria. Deceased patients were older (p=0.015) and had shorter walking distance (p=0.003). Risk criteria were worse for symptom progression, WHO functional class, walking distance and for the overall number of red criteria. ROC-curve analysis showed that symptom progression (c-statistic 0.695, p=0.048), walking distance (0.748, p=0.012) and the overall number of red flags (0.710, p=0.033) were the only elements associated with 12 month mortality.Abstract P171 Table 1Median/%Red flags, n(%) Symptom progressionN/A11 (10.6)NT-proBNP (ng/L)60.52 (1.9)WHO functional classN/A13 (12.5)6 min walk distance (m)29528 (28)Echo RA area (cm2)17.5 5 (7.4)Right heart catheter (any criterion)N/A13 (19.1)ConclusionsThe ESC risk assessment criteria are associated with 12 month mortality in this cohort when all criteria are collated. Further work in a large cohort is needed to confirm the clinical utility of these criteria.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/thoraxjnl-2017-210983.313</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0040-6376 |
ispartof | Thorax, 2017-12, Vol.72 (Suppl 3), p.A175 |
issn | 0040-6376 1468-3296 |
language | eng |
recordid | cdi_proquest_journals_1970930940 |
source | Alma/SFX Local Collection |
subjects | Cardiology Medical prognosis Mortality Pulmonary hypertension Risk assessment Walking |
title | P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T03%3A30%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P171%E2%80%85Are%20the%20european%20society%20of%20cardiology%20pulmonary%20hypertension%20guideline%20risk%20assessment%20criteria%20associated%20with%2012-month%20mortality?&rft.jtitle=Thorax&rft.au=Sharp,%20C&rft.date=2017-12&rft.volume=72&rft.issue=Suppl%203&rft.spage=A175&rft.pages=A175-&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136/thoraxjnl-2017-210983.313&rft_dat=%3Cproquest_bmj_p%3E1970930940%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1970930940&rft_id=info:pmid/&rfr_iscdi=true |